Phase 2Active, not recruiting
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD (SUSPIRE-1)
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
- Sponsor
- Areteia Therapeutics (Industry)
- Enrollment
- 30 planned
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dexpramipexole Dihydrochloride
- Ages
- adults, older adults
- Registry
- NCT06533553
Full record on ClinicalTrials.gov
From the registry
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Primary outcomes
- Geometric mean change in the blood AEC from baseline to Week 16
History
Study completion
Primary completion
Last registry update
Registered
Started